What is AnaptysBio?
Founded in 2005 and headquartered in California, AnaptysBio operates at the intersection of advanced immunology and drug development. The company specializes in the discovery and development of novel antibody therapeutics, leveraging a robust research and development engine to target complex inflammatory diseases and immuno-oncology indications. By focusing on innovative antibody-based solutions, AnaptysBio aims to redefine treatment paradigms for patients suffering from chronic conditions, effectively bridging the gap between early-stage scientific discovery and clinical-grade pharmaceutical applications.
How much funding has AnaptysBio raised?
AnaptysBio has raised a total of $265.9M across 6 funding rounds:
Series A
$2M
Series B
$33.9M
Series C
$8M
Debt
$2M
Stock Offering
$75M
Stock/Share Issuance
$145M
Series A (2006): $2M with participation from Avalon Ventures
Series B (2007): $33.9M led by Alloy Ventures, WS Investment Co., Numenor Ventures, Novo A/S, Frazier Healthcare Partners, and Avalon Ventures
Series C (2011): $8M, investors not publicly disclosed
Debt (2013): $2M, investors not publicly disclosed
Stock Issuance/Offering (2017): $75M, investors not publicly disclosed
Stock/Share Issuance (2026): $145M with participation from Palo Alto Investors, Janus Henderson Group, Adage Capital Management, Ally Bridge Group, Affinity Asset Advisors, Point72 Ventures, Woodline Partners, StemPoint Capital, TCG Crossover, and Vestal Point Capital
Key Investors in AnaptysBio
Palo Alto Investors
Palo Alto Investors LP is a physician-led investment firm specializing in healthcare-focused investments, leveraging deep, fundamental research since 1989 to identify long-term opportunities in the sector.
Janus Henderson Group
Janus Henderson is a global investment management firm that provides a broad range of investment solutions and advisory services to institutional investors, financial professionals, and individual clients.
Adage Capital Management
Adage Capital Management is a prominent money management firm headquartered in Boston, Massachusetts, primarily focused on S&P 500 assets.
What's next for AnaptysBio?
With the infusion of $145M, AnaptysBio is well-positioned to accelerate its clinical pipeline and expand its research capabilities. The strategic allocation of this capital will likely focus on advancing lead candidates through late-stage clinical trials and strengthening the company's intellectual property portfolio. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward commercial readiness and the potential for strategic partnerships that can scale its therapeutic impact globally. Investors will be closely monitoring the company's ability to translate its scientific milestones into tangible clinical outcomes, which remains the primary driver of long-term value in the biotechnology sector.
See full AnaptysBio company page
